These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 22926407)

  • 1. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy.
    Xueyi L; Lina C; Zhenbiao W; Qing H; Qiang L; Zhu P
    J Clin Immunol; 2013 Jan; 33(1):151-61. PubMed ID: 22926407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis.
    Fattahi MJ; Ahmadi H; Jafarnezhad-Ansariha F; Mortazavi-Jahromi SS; Rehm BHA; Cuzzocrea S; Matsuo H; Mirshafiey A
    Biomed Pharmacother; 2018 Apr; 100():495-500. PubMed ID: 29477913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy.
    Chen DY; Chen YM; Chen HH; Hsieh CW; Lin CC; Lan JL
    Arthritis Res Ther; 2011 Jul; 13(4):R126. PubMed ID: 21801431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis.
    Lina C; Conghua W; Nan L; Ping Z
    J Clin Immunol; 2011 Aug; 31(4):596-605. PubMed ID: 21562776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Anti-TNF Therapy on CD4+ and CD8+ Cell Subsets in Ankylosing Spondylitis.
    Dulic S; Vasarhelyi Z; Bajnok A; Szalay B; Toldi G; Kovacs L; Balog A
    Pathobiology; 2018; 85(3):201-210. PubMed ID: 29212085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.
    Hull DN; Williams RO; Pathan E; Alzabin S; Abraham S; Taylor PC
    Clin Exp Immunol; 2015 Sep; 181(3):401-6. PubMed ID: 25766640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha blockade leads to decreased peripheral T cell reactivity and increased dendritic cell number in peripheral blood of patients with ankylosing spondylitis.
    Pang L; Wang L; Suo T; Hao H; Fang X; Jia J; Huang F; Tang J
    J Rheumatol; 2008 Nov; 35(11):2220-8. PubMed ID: 19004053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients.
    Milanez FM; Saad CG; Viana VT; Moraes JC; Périco GV; Sampaio-Barros PD; Goncalves CR; Bonfá E
    Arthritis Res Ther; 2016 Feb; 18():52. PubMed ID: 26912133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
    Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.
    Lord PA; Farragher TM; Lunt M; Watson KD; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2010 Mar; 49(3):563-70. PubMed ID: 20032223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus.
    Wang D; Huang S; Yuan X; Liang J; Xu R; Yao G; Feng X; Sun L
    Cell Mol Immunol; 2017 May; 14(5):423-431. PubMed ID: 26435067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
    de Vries MK; van der Horst-Bruinsma IE; Nurmohamed MT; Aarden LA; Stapel SO; Peters MJ; van Denderen JC; Dijkmans BA; Wolbink GJ
    Ann Rheum Dis; 2009 Apr; 68(4):531-5. PubMed ID: 18375542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy.
    McGovern JL; Nguyen DX; Notley CA; Mauri C; Isenberg DA; Ehrenstein MR
    Arthritis Rheum; 2012 Oct; 64(10):3129-38. PubMed ID: 22674488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of TNF inhibitor on innate inflammatory and Th17 cytokines in stimulated whole blood from rheumatoid arthritis patients.
    Zivojinovic S; Pejnovic N; Sefik-Bukilica M; Kovacevic L; Soldatovic I; Bugarski D; Mojsilovic S; Damjanov N
    Inflammopharmacology; 2012 Dec; 20(6):323-30. PubMed ID: 22733231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy.
    Kwon SR; Lim MJ; Suh CH; Park SG; Hong YS; Yoon BY; Kim HA; Choi HJ; Park W
    Rheumatol Int; 2012 Aug; 32(8):2523-7. PubMed ID: 21833531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the T helper 17 axis in ankylosing spondylitis.
    Taylan A; Sari I; Kozaci DL; Yuksel A; Bilge S; Yildiz Y; Sop G; Coker I; Gunay N; Akkoc N
    Rheumatol Int; 2012 Aug; 32(8):2511-5. PubMed ID: 21833527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.